Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Morgan Stanley, Gilead
Morgan Stanley upgrades Gilead on HIV treatment growth
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.
Gilead upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley upgraded Gilead (GILD) to Overweight from Equal Weight with a price target of $113, up from $87. The firm sees the potential for
Morgan Stanley Upgrades Vir Biotechnology (VIR)
Fintel reports that on January 9, 2025, Morgan Stanley upgraded their outlook for Vir Biotechnology (NasdaqGS:VIR) from Equal-Weight to Overweight. Analyst Price Forecast Suggests 141.11% Upside As of December 23,
Morgan Stanley upgrades Vir Biotechnology to 'overweight,' raises PT to $20
Morgan Stanley (NYSE:MS) analysts have upgraded Vir Biotechnology (NASDAQ:VIR) to an "overweight" rating, shifting from "equal-weight," and have also increased their price target to $20 from $10. The analysts flagged
Hosted on MSN
5h
Surge in IB Activities & Solid Trading to Support MS' Q4 Earnings
The performance of Morgan Stanley’s MS trading business (constituting a significant portion of its top line) is expected to ...
1d
Morgan Stanley promotes 173 employees to managing directors, source says
Wall Street giant Morgan Stanley promoted 173 of its employees to managing director roles this year, marking a 12% increase ...
1d
Morgan Stanley Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
JP Morgan analyst Kian Abouhossein maintained a Neutral rating and boosted the price target from $100 to $104 on Dec. 6, 2024 ...
1d
Morgan Stanley (MS) Scheduled to Post Quarterly Earnings on Thursday
Morgan Stanley (NYSE:MS – Get Free Report) is set to issue its quarterly earnings data before the market opens on Thursday, ...
bovnews
1d
What’s Causing Morgan Stanley (MS) Stock’s 23.65% Jump Over the Last Six Months?
Morgan Stanley (MS) stock saw a decline, ending the day at $126.88 which represents a decrease of $-1.76 or -1.37% from the prior close of $128.64. The stock opened at $129.65 and touched a low of ...
3d
Morgan Stanley's Options Frenzy: What You Need to Know
Investors with a lot of money to spend have taken a bearish stance on Morgan Stanley MS. And retail traders should know. We ...
2d
Morgan Stanley stock underperforms Tuesday when compared to competitors
Shares of Morgan Stanley MS shed 1.37% to $126.88 Tuesday, on what proved to be an all-around dismal trading session for the ...
4d
Morgan Stanley (MS) Gets a Buy from Barclays
In a report released today, Jason Goldberg from Barclays maintained a Buy rating on Morgan Stanley (MS – Research Report), with a price target ...
3d
2,526 Shares in Morgan Stanley (NYSE:MS) Acquired by Neville Rodie & Shaw Inc.
Neville Rodie & Shaw Inc. bought a new stake in shares of Morgan Stanley (NYSE:MS – Free Report) during the 4th quarter, ...
1d
Morgan Stanley stock outperforms competitors on strong trading day
Morgan Stanley closed $8.38 short of its 52-week high ($136.24), which the company achieved on November 25th.
3d
Morgan Stanley price target raised to $146 from $140 at BofA
BofA raised the firm’s price target on Morgan Stanley (MS) to $146 from $140 and keeps a Buy rating on the shares. Strong Q3 results ...
20h
on MSN
Morgan Stanley outlook positive on truck OEMs for 2025
Morgan Stanley expects improving freight conditions and upcoming emissions regulations to boost global truck manufacturers in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback